Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study of the Effect of Intravenous Aflibercept Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
Brief Summary: This study was designed to characterize the effect of aflibercept in participants with advanced chemoresistant ovarian cancer.

Primary objective: Compare the effect of aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) to placebo treatment on repeat paracentesis in symptomatic malignant ascites in participants with advanced ovarian cancer

Secondary objectives: Safety, tolerability, paracentesis-related parameters, participant-reported outcome.


Options:
A: Arm Label: Arm I (PLD, atezolizumab); Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab, Procedure: Computed Tomography, Drug: Pegylated Liposomal Doxorubicin Hydrochloride, Other: Quality-of-Life Assessment | Arm Label: Arm II (PLD, bevacizumab, atezolizumab); Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab, Biological: Bevacizumab, Procedure: Computed Tomography, Drug: Pegylated Liposomal Doxorubicin Hydrochloride, Other: Quality-of-Life Assessment | Arm Label: Arm III (PLD, bevacizumab); Type: ACTIVE_COMPARATOR; Interventions: Biological: Bevacizumab, Procedure: Computed Tomography, Drug: Pegylated Liposomal Doxorubicin Hydrochloride, Other: Quality-of-Life Assessment | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Arm I (PLD, atezolizumab), Arm II (PLD, bevacizumab, atezolizumab) | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm II (PLD, bevacizumab, atezolizumab), Arm III (PLD, bevacizumab) | Intervention Type: PROCEDURE; Name: Computed Tomography; Assigned to Arm(s): Arm I (PLD, atezolizumab), Arm II (PLD, bevacizumab, atezolizumab), Arm III (PLD, bevacizumab) | Intervention Type: DRUG; Name: Pegylated Liposomal Doxorubicin Hydrochloride; Assigned to Arm(s): Arm I (PLD, atezolizumab), Arm II (PLD, bevacizumab, atezolizumab), Arm III (PLD, bevacizumab) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (PLD, atezolizumab), Arm II (PLD, bevacizumab, atezolizumab), Arm III (PLD, bevacizumab)
B: Arm Label: Standard treatment; Type: OTHER; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Bevacizumab | Arm Label: Carboplatin + Paclitaxel + Bevacizumab + Rucaparib; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Bevacizumab, Drug: Rucaparib | Arm Label: Carboplatin + Paclitaxel + Rucaparib; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Rucaparib | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Carboplatin + Paclitaxel + Bevacizumab + Rucaparib, Carboplatin + Paclitaxel + Rucaparib, Standard treatment | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Carboplatin + Paclitaxel + Bevacizumab + Rucaparib, Carboplatin + Paclitaxel + Rucaparib, Standard treatment | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Carboplatin + Paclitaxel + Bevacizumab + Rucaparib, Standard treatment | Intervention Type: DRUG; Name: Rucaparib; Assigned to Arm(s): Carboplatin + Paclitaxel + Bevacizumab + Rucaparib, Carboplatin + Paclitaxel + Rucaparib
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Arm Label: Aflibercept; Type: EXPERIMENTAL; Interventions: Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Intervention Type: DRUG; Name: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept, Placebo
D: Arm Label: Olaparib 300mg tablets; Type: EXPERIMENTAL; Interventions: Drug: Olaparib 300mg tablets | Arm Label: Placebo tablets; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match olaparib 300mg | Intervention Type: DRUG; Name: Olaparib 300mg tablets; Assigned to Arm(s): Olaparib 300mg tablets | Intervention Type: DRUG; Name: Placebo to match olaparib 300mg; Assigned to Arm(s): Placebo tablets

Answer: C